Evidence map›Paper›PMID 28144273›Full record

ArticleArchives of medical science : AMS2017

Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis.

Belinda A Di Bartolo, Nisha Schwarz, Jordan Andrews, Stephen J Nicholls

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Lipid management in patients with chronic kidney disease.Nature reviews. Nephrology · 2018 · on this map
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Belinda A Di BartoloSouth Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia.
Nisha SchwarzSouth Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia.
Jordan AndrewsSouth Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia.
Stephen J NichollsSouth Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-density lipoproteins (HDL) have received considerable interest as a target for the development of novel anti-atherosclerotic agents beyond conventional approaches to lipid lowering. While a number of approaches have focused on modifying remodeling and expression pathways implicated in the regulation of HDL levels, an additional approach involves simply infusions of delipidated HDL. Several groups have advanced HDL infusions to clinical development with intriguing signs suggesting potentially favorable impacts at the level of the artery wall. The findings of early studies of infusional HDL therapies will be reviewed.

Indexed as

atherosclerosisclinical trialshigh density lipoproteinimaginglipidsrisk factors

Identifiers

PMID28144273
PMCPMC5206363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.